SC
NEUP

Shay Capital’s Neuphoria Therapeutics NEUP Stock Holding History

Shay Capital’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$681K Buy
155,822
+4,812
+3% +$23.2K 0.04% 252
2026
Q1 		$615K Sell
151,010
-18,049
-11% -$76.3K 0.05% 230
2025
Q4 		$656K Buy
+169,059
New +$1.2M 0.07% 239

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Shay Capital's NEUP Position: Q2 2026 in Review

Shay Capital increased its Neuphoria Therapeutics (NEUP) stake by 3.2% in Q2 2026, buying an estimated $23.2K and bringing the position to 155,822 shares worth $681K. The position accounts for 0.04% of the portfolio, ranked #252.

Shay Capital first reported a position in NEUP in Q4 2025 and has held it in 3 quarters since. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • Shay Capital held 155,822 shares of Neuphoria Therapeutics worth $681K as of Q2 2026.
  • Shay Capital bought 4,812 Neuphoria Therapeutics shares in Q2 2026, an estimated $23.2K.
  • Neuphoria Therapeutics made up 0.04% of Shay Capital's portfolio in Q2 2026, its #252 holding.
  • Shay Capital first reported a position in Neuphoria Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.